FDA Calls for Boxed Warnings for CAR T-Cell Immunotherapies
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Following an investigation that began in November 2023, the FDA now requires boxed warnings regarding T-cell malignancies on all BCMA- and CD19-directed T-cell products.
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo…
Experiencing guilt after cancer treatment may sound unexpected, but it’s actually quite common. Clinical psychologist Catherine Powers, Ph.D., and senior social work counselor Kendolyn Shankle…
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
An abstract is unavailable.
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Agencje rejestrujące leki, takie jak FDA czy EMA, mogą dopuszczać leki w procedurze przyspieszonej lub warunkowo. Bywa, że jeśli lek okaże się nieskuteczny, może zostać…
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.